|Bid||4.74 x 800|
|Ask||7.70 x 1800|
|Day's Range||4.85 - 5.13|
|52 Week Range||4.73 - 21.97|
|Beta (3Y Monthly)||1.38|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2019 - Mar 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.17|
WAYNE, Pa., May 24, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases,.
Rigel (RIGL) enrolls first patient in a pivotal label expansion study evaluating its approved drug, Tavalisse, in patients with antibody autoimmune hemolytic anemia.
Aclaris (ACRS) delivered earnings and revenue surprises of -13.75% and -1.74%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Wayne, Pennsylvania-based company said it had a loss of 91 cents per share. The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
It would be Aclaris’ first internally-developed novel compound to enter the clinical phase of development and its first inflammatory indication adjacent to dermatology. Aclaris expects to begin a Phase 1 clinical trial of ATI-450, an investigational compound, in the second half of 2019. In April 2019, Aclaris completed enrollment of more than 1,000 patients across two Phase 3 pivotal clinical trials (THWART-1 and THWART-2) investigating A-101 45% Topical Solution, an investigational drug, for the treatment of common warts, and expects to complete enrollment of Aclaris’ open-label safety extension trial (WART-303) evaluating the long-term safety of A-101 45% Topical Solution during the second quarter of 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The most recent earnings release Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) announced in December 201...
WAYNE, Pa., May 01, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases,.
Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that it has submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for ATI-450, an oral MK2 inhibitor, for the treatment of rheumatoid arthritis (RA).
Aclaris Therapeutics, Inc. (ACRS), a physician-led biopharmaceutical company focused on immuno-inflammatory and dermatological diseases, today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 10,265,258 covering methods of treating alopecia areata (AA) using ruxolitinib or isotopic forms of ruxolitinib. This newly issued patent is the latest in a series of patents granted by the USPTO which are exclusively licensed to Aclaris by The Trustees of Columbia University in the City of New York in connection with Aclaris’ janus kinase (JAK) inhibitor program for hair loss disorders. This IP arose out of the novel breakthrough research conducted by Dr. Angela Christiano and her team at Columbia University.
Wall Street issued a buy recommendation rating for all three stocks, increasing the likelihood of them outperforming the S&P 500 Index over the next 52 weeks. Warning! GuruFocus has detected 2 Warning Sign with CTMX. Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives.
WAYNE, Pa., March 27, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases,.
On a per-share basis, the Wayne, Pennsylvania-based company said it had a loss of 99 cents. The specialty pharmaceutical company posted revenue of $3.7 million in the period. For the year, the company ...
Product Sales of $3.9 Million for Fiscal Year 2018Initiates Financial Guidance for Full Year 2019Management to Host Conference Call at 8:00 AM ET today WAYNE, Pa., March 18,.
NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Aclaris Therapeutics, Inc. (NASDAQ: ACRS ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 18, 2019 at 8:00 ...
WAYNE, Pa., March 08, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a physician-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases,.
Aclaris Therapeutics, Inc. (ACRS), a dermatologist-led biopharmaceutical company focused on dermatological and immuno-inflammatory diseases, today announced that it received approval from the Swedish Medical Products Agency to market ESKATA® (hydrogen peroxide) cutaneous solution, 685 mg for the treatment in adults of seborrheic keratoses that are not pedunculated and have up to a maximum diameter of 15 mm each. Aclaris also has received approval to market the medicine in the United Kingdom, Iceland, Belgium, and Finland. Aclaris is seeking a commercial partner or partners to market the medicine as an aesthetic skin treatment in various European countries with the brand name ESKATA in Finland, Iceland, Netherlands, Norway, Portugal, Spain, Sweden, Czech Republic, Belgium and the brand name ESKERIELE® in Austria, France, Germany, Ireland, Italy, and the United Kingdom.
Phase 2 Clinical Study Results in Treatment of Common Warts Selected for Oral Presentations WAYNE, Pa., Feb. 19, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a.
Neal Walker became the CEO of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) in 2012. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...
WAYNE, Pa., Jan. 02, 2019 -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a dermatologist-led biopharmaceutical company committed to identifying, developing, and commercializing.
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 5.7% in the 12 months ending October 26 […]
Aclaris Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.